Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E34.36 EPS (ttm)0.65 Insider Own2.52% Shs Outstand302.79M Perf Week3.30%
Market Cap6.74B Forward P/E14.31 EPS next Y1.55 Insider Trans-0.01% Shs Float295.56M Perf Month2.21%
Income207.76M PEG1.81 EPS next Q0.23 Inst Own86.45% Short Float2.83% Perf Quarter4.56%
Sales1.83B P/S3.68 EPS this Y90.69% Inst Trans-1.96% Short Ratio3.74 Perf Half Y-1.16%
Book/sh7.48 P/B2.97 EPS next Y25.39% ROA6.85% Short Interest8.37M Perf Year27.30%
Cash/sh3.28 P/C6.77 EPS next 5Y19.00% ROE8.74% 52W Range16.15 - 24.34 Perf YTD-7.29%
Dividend Est.- P/FCF23.02 EPS past 5Y-21.77% ROI8.47% 52W High-8.63% Beta0.53
Dividend TTM- Quick Ratio3.30 Sales past 5Y17.31% Gross Margin96.04% 52W Low37.75% ATR (14)0.53
Dividend Ex-Date- Current Ratio3.34 EPS Y/Y TTM15.07% Oper. Margin9.34% RSI (14)61.51 Volatility2.27% 2.28%
Employees1310 Debt/Eq0.10 Sales Y/Y TTM13.60% Profit Margin11.35% Recom1.62 Target Price26.74
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q392.82% Payout0.00% Rel Volume1.54 Prev Close21.90
Sales Surprise-0.14% EPS Surprise17.54% Sales Q/Q13.15% EarningsFeb 06 AMC Avg Volume2.24M Price22.24
SMA205.86% SMA500.23% SMA2005.42% Trades Volume3,445,479 Change1.55%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Initiated BTIG Research Buy $27
Dec-15-23Initiated Citigroup Buy $31
Sep-26-23Initiated H.C. Wainwright Buy $28
Aug-22-23Reiterated Oppenheimer Outperform $25 → $29
Aug-08-23Initiated SVB Securities Market Perform $18
Jul-11-23Resumed Morgan Stanley Equal-Weight $21
May-10-23Resumed Piper Sandler Overweight $28
Mar-09-23Initiated Wells Fargo Overweight $23
Jan-26-23Initiated Credit Suisse Outperform $29
Oct-18-22Initiated JMP Securities Mkt Outperform $26
Feb-27-24 04:05PM
Feb-26-24 07:42AM
Feb-23-24 01:11PM
Feb-19-24 08:00AM
08:30AM Loading…
Feb-14-24 08:30AM
Feb-13-24 08:00AM
Feb-12-24 09:35AM
Feb-10-24 05:06AM
Feb-09-24 09:35AM
Feb-08-24 06:50PM
Feb-07-24 07:01PM
10:47AM Loading…
Feb-06-24 08:45PM
Feb-01-24 04:05PM
Jan-30-24 10:00AM
Jan-29-24 09:40AM
Jan-25-24 08:00AM
Jan-23-24 04:05PM
Jan-22-24 05:00PM
Jan-21-24 01:16PM
11:21AM Loading…
Jan-19-24 11:21AM
Jan-18-24 04:05PM
Jan-17-24 11:29AM
Jan-11-24 09:40AM
Jan-08-24 04:40PM
Jan-07-24 04:00PM
Jan-02-24 04:05PM
Dec-19-23 10:16AM
Dec-12-23 08:54AM
Dec-07-23 04:05PM
Dec-05-23 01:51PM
Dec-04-23 07:26PM
Dec-01-23 11:32AM
Nov-29-23 10:45AM
Nov-21-23 04:05PM
Nov-17-23 01:33PM
Nov-10-23 09:00AM
Nov-09-23 04:43PM
Nov-08-23 05:24PM
Nov-06-23 09:47AM
Nov-03-23 12:11PM
Nov-02-23 11:23AM
Nov-01-23 07:00PM
Oct-30-23 10:00AM
Oct-28-23 05:06AM
Oct-27-23 04:58AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
Oct-22-23 02:30AM
Oct-19-23 06:51PM
Oct-18-23 04:05PM
Oct-12-23 11:40AM
Oct-09-23 02:03AM
Oct-02-23 09:49AM
Sep-20-23 02:15PM
Sep-18-23 09:16AM
Sep-16-23 05:06AM
Sep-15-23 10:23AM
Sep-13-23 11:23AM
Sep-12-23 08:00AM
Sep-11-23 12:31PM
Sep-08-23 11:30AM
Sep-07-23 08:43AM
Sep-06-23 09:33AM
Sep-05-23 11:40AM
Sep-04-23 10:34AM
Sep-01-23 11:31AM
Aug-31-23 04:05PM
Aug-30-23 08:00AM
Aug-29-23 06:52PM
Aug-28-23 09:30AM
Aug-25-23 11:49AM
Aug-24-23 08:00AM
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haley Patrick J.EVP, CommercialFeb 23Sale21.4547,0201,008,579384,866Feb 27 06:58 PM
JOHNSON DAVID EDWARDDirectorFeb 21Buy20.70190,0003,932,7341,100,730Feb 22 05:08 PM
Haley Patrick J.EVP, CommercialDec 14Option Exercise16.2950,000814,500357,687Dec 14 07:56 PM
Haley Patrick J.EVP, CommercialDec 14Sale23.3550,0001,167,500307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 13Sale23.0125,000575,250533,345Dec 14 07:55 PM
Haley Patrick J.EVP, CommercialDec 12Sale22.5014,149318,352307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 04Sale22.0625,000551,500558,345Dec 04 06:22 PM
Hessekiel JeffreyEVP, General Counsel & SecNov 30Sale22.0125,000550,250583,345Dec 04 06:22 PM
JOHNSON DAVID EDWARDDirectorNov 27Buy21.61120,4092,602,038910,730Nov 29 04:30 PM
JOHNSON DAVID EDWARDDirectorNov 27Sale21.61120,4092,602,038790,321Nov 29 04:30 PM
Aftab DanaCSO/EVP Disc & Trans ResearchAug 30Sale22.474,600103,362399,943Sep 01 08:15 PM
MORRISSEY MICHAELPresident and CEOAug 28Option Exercise15.31360,0005,511,600945,496Aug 30 09:48 PM
Senner Christopher J.EVP and CFOAug 04Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 04Sale20.6860,0001,240,800571,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03Sale20.5160,0001,230,600571,631Aug 07 09:20 PM
Haley Patrick J.EVP, CommercialAug 03Sale20.6730,553631,531285,467Aug 07 08:24 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01Option Exercise14.7455,710821,165627,686Aug 03 08:02 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01Sale19.6355,7101,093,587571,976Aug 03 08:02 PM
Hessekiel JeffreyEVP, General Counsel & SecApr 05Option Exercise14.7413,930205,328621,365Apr 05 08:57 PM
Hessekiel JeffreyEVP, General Counsel & SecApr 05Sale20.0138,930778,989582,435Apr 05 08:57 PM
WYSZOMIERSKI JACK LDirectorMar 10Option Exercise6.3040,000252,000332,767Mar 14 08:22 PM
WYSZOMIERSKI JACK LDirectorMar 10Sale16.6115,300254,133317,467Mar 14 08:22 PM